NPIL Pharma Agrees to Acquire Pfizer's Morpeth Manufacturing Facility, Signs Supply Agreement

June 16, 2006
Patricia Van Arnum

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

ePT--the Electronic Newsletter of Pharmaceutical Technology

NPIL Pharma, a subsidiary of Nicholas Piramal India Limited (Mumbai, India) has agreed to acquire the Morpeth, Northumberland, UK, manufacturing facility of Pfizer Inc. (New York, NY).

NPIL Pharma, a subsidiary of Nicholas Piramal India Limited (Mumbai,India, www.nicholaspiramal.com)has agreed to acquire the Morpeth, Northumberland, UK, manufacturingfacility of Pfizer Inc. (New York, NY, www.pfizer.com). The integrated site hasproduction and supply-chain capabilities that cover activepharmaceutical ingredients, finished dosage, packaging, anddistribution.  

NPIL Pharma expects to complete the deal by June 19. In acquiring thefacility, NPIL Pharma also has entered into a supply agreement, worthup to $350 million, with Pfizer through November 2011.

The deal expands NPIL Pharma's sourcing relationship with Pfizer. NPILalready has a seven-year agreement, signed in December 2005, to provideprocess development and scale-up services to Pfizer's animal healthdivision.

The Morpeth acquisition is NPIL's third in the United Kingdom,following its purchase of Rhodia's (Paris, France, www.rhodia.com)inhalation anesthetics business in December 2004 and Avecia's custommanufacturing business in December 2005.

Related Content:

PharmTech News | Manufacturing